Teva and Fosun ink deal on TEV-56278 development

Israel’s Teva Pharmaceutical Industries (NYSE and TASE: TEVA) and Shanghai Fosun Pharmaceutical (HKEX: 02196) have entered a strategic partnership for the development of investigational TEV-56278, an anti-PD1-IL2 ATTENUKINE therapy.

Teva noted that its internally developed ATTENUKINE technology provides a new mechanism of action, potentially offering high efficacy and low toxicity in a broad array of oncology indications.

Under the terms of the agreement, which aims to accelerate clinical data generation, Fosun Pharma is granted an exclusive license to develop, manufacture and commercialize TEV-56278 in Chinese mainland, Hong Kong Special Administrative Region (SAR), Macau SAR and Taiwan region and select Southeast Asian countries. Financial terms of the deal were not disclosed.